<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="54851">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02392078</url>
  </required_header>
  <id_info>
    <org_study_id>LAANTERN</org_study_id>
    <nct_id>NCT02392078</nct_id>
  </id_info>
  <brief_title>Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate System</brief_title>
  <acronym>LAANTERN</acronym>
  <official_title>Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate System (LAANTERN) Prospective Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Monteris Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Monteris Medical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The NeuroBlate® System (NBS) is a minimally invasive robotic laser thermotherapy tool that
      is being manufactured by Monteris Medical. Since it received FDA clearance in April 2013,
      the NBS has been used in over 300 procedures conducted at approximately 20 leading
      institutions across United States. This is a prospective, multi-center registry that will
      include data collection up to 12 months to evaluate procedural success, local control
      failure rate, and QoL in up to 1,000 patients and up to 50 sites.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Procedural Success</measure>
    <time_frame>up to 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Local control Failure Rate</measure>
    <time_frame>up to 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>up to 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety (Reportable adverse events)</measure>
    <time_frame>up to 12 months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Metastatic Brain Tumor</condition>
  <condition>Primary Brain Tumor</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>NeuroBlate System</intervention_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who preferred management for soft tissue through interstitial irradiation or
        thermal therapy by the NeuroBlate® System, in the opinion of the treating physician
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient or legally authorized representative provides written authorization and/or
             consent per institution and geographical requirements

          2. Patient who is to undergo thermal therapy by the NeuroBlate® System for treatment of
             their neurological disorder

        Exclusion Criteria:

          1. Patient who is, or is expected to be inaccessible for follow-up

          2. Patient meets any exclusion criteria required by local law (e.g. age)

          3. Other concurrent medical or other condition (chronic or acute in nature) that in the
             opinion of the investigator may prevent participation or otherwise render patient
             ineligibility for the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Audrey Singh</last_name>
    <phone>763-253-4717</phone>
    <email>asingh@monteris.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California, San Diego</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lara Rose</last_name>
      <phone>858-822-6575</phone>
      <email>ljrose@ucsd.edu</email>
    </contact>
    <investigator>
      <last_name>Clark Chen, md</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yale University School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Judith Hess</last_name>
      <phone>203-737-6259</phone>
      <email>judith.hess@yale.edu</email>
    </contact>
    <investigator>
      <last_name>Veronica Chiang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Florida Hospital</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karin Donaldson</last_name>
      <phone>407-303-2944</phone>
      <email>karin.donaldson@flhosp.org</email>
    </contact>
    <investigator>
      <last_name>Melvin Field, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cathy T Lauridsen</last_name>
      <phone>913-588-4573</phone>
      <email>clauridsen2@kumc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeanine Wade</last_name>
      <phone>314-362-2940</phone>
      <email>jeanine.wade@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Eric Leuthardt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristy Averette</last_name>
      <phone>919-684-0380</phone>
      <email>kristy.l.johnson@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Peter Fecci, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wake Forest</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wendy Jenkins</last_name>
      <phone>336-716-3842</phone>
      <email>wejenkin@wakehealth.edu</email>
    </contact>
    <investigator>
      <last_name>Stephen Tatter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospitals Cleveland Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Fahrion</last_name>
      <phone>216-983-5169</phone>
      <email>jennifer.fahrion@uhhospitals.org</email>
    </contact>
    <investigator>
      <last_name>Andrew Sloan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dee Walick</last_name>
      <phone>216-445-8797</phone>
      <email>walickd@ccf.org</email>
    </contact>
    <investigator>
      <last_name>Alireza Mohammadi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kara Pigott</last_name>
      <phone>215-503-9110</phone>
      <email>kara.pigott@jefferson.edu</email>
    </contact>
    <investigator>
      <last_name>Kevin Judy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of British Columbia</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Camille Hunt</last_name>
      <phone>604-875-4111</phone>
      <phone_ext>62560</phone_ext>
      <email>camille.hunt@ubc.ca</email>
    </contact>
    <investigator>
      <last_name>Brian Toyota, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>October 13, 2016</lastchanged_date>
  <firstreceived_date>March 12, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Procedural Success</keyword>
  <keyword>Progression</keyword>
  <keyword>Quality of Life</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
